Polaryx Therapeutics, Inc. PLYX
—
2.09
(0.05)
(2.34%)
as of 25 Sep
- Market cap
- $106.7M
- P/E
- 0.0×
Follow PLYX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+2 more TTM periods Free account |
|
| (169.05%) | 0.00% | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(91.27%) | 0.00% | 0.00% | — | |
Free Cash Flow per Share |
(0.17) | (0.16) | 0.00 | 0.00 | |
Free Cash Flow |
(8.23) | (7.57) | (8.08) | — | |
Piotroski F-Score |
1.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(36.63%) | (136.03%) | (83.27%) | 0.00% | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Interest Coverage |
0.00 | — | — | — | |
Operating CF/Net income |
0.82 | 0.00 | 0.00 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(0.17) | (0.16) | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | — | — | — |
Columns are period end dates